Interleukin-7
Also known as: CYT-007, CYT107, IL-7, Lymphopoietin-1, NT-I7, rhIL-7, rhIL-7-hyFc
Source Interleukin-7 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human IL-7 is being evaluated to enhance immune reconstitution in lymphopenic patients, augment vaccine responses, and support cancer immunotherapy.
Mechanism of Action
Binds IL-7 receptor (IL-7Rα/γc) activating JAK1/3-STAT5 signaling, promoting survival, proliferation and differentiation of naive and memory T cells.
Routes of Administration
Goals & Uses
- HIV-associated immune deficiencyInfectious Disease / ImmunologyModerate
- Sepsis-induced lymphopenia reversalCritical Care / ImmunologyModerate
- Graft-versus-host disease mitigation post-HSCTTransplant ImmunologyLow
- immune reconstitutionImmunologyModerate
- Cancer immunotherapy augmentationOncologyLow
- Cancer immunotherapyOncologyModerate
- Vaccine immune response enhancementVaccinologyLow
- T-cell immune reconstitutionImmunologyModerate
Contraindications
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Hypersensitivity to IL-7 or excipientsAllergy / ImmunologyHigh
- Active graft-versus-host diseaseTransplant ImmunologyHigh
- Uncontrolled systemic infectionInfectious DiseaseModerate
- Hematologic malignancy with T-cell lineage involvementOncologyHigh
- Active autoimmune diseaseAutoimmunityHigh
- severe lymphoproliferative disordersHematologyHigh
Adverse Effects
- Skin rash / eosinophiliaDermatologic / HematologicUncommon
- lymphocytosisLaboratoryCommon
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- Autoimmune manifestationsImmunologicRare
- Transient lymphadenopathyLymphaticCommon
- Flu-like symptoms / feverSystemicCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- Checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Moderate
- JAK inhibitors (e.g., ruxolitinib, tofacitinib)High
- Immunosuppressants (e.g., tacrolimus, cyclosporine)Moderate
- CorticosteroidsModerate
- calcineurin inhibitors (e.g., tacrolimus)Moderate
Population Constraints
- Patients with T-cell malignanciesOncologyAbsolute
- Pediatric patientsAgeRelative
- Patients with pre-existing autoimmune diseaseAutoimmuneRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Elderly patients (>65 years)AgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted for immune reconstitution studies.
- United StatesInvestigationalIND in place for HIV and oncology trials.
- United KingdomInvestigationalNo MHRA-approved IL-7 therapeutic product; clinical trial access only as of 2024.
Not approved for clinical use; currently in Phase I/II trials for HIV, cancer, and post‑transplant immune recovery.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Interleukin-7?
Recombinant human IL-7 is being evaluated to enhance immune reconstitution in lymphopenic patients, augment vaccine responses, and support cancer immunotherapy.
What is Interleukin-7 used for?
Interleukin-7 is educationally associated with: HIV-associated immune deficiency, Sepsis-induced lymphopenia reversal, Graft-versus-host disease mitigation post-HSCT, immune reconstitution, Cancer immunotherapy augmentation, Cancer immunotherapy, Vaccine immune response enhancement, T-cell immune reconstitution. Educational only — not medical advice.
How is Interleukin-7 administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Interleukin-7?
Reported adverse effects include: Skin rash / eosinophilia, lymphocytosis, Flu‑like symptoms, Injection site reactions, Thrombocytopenia, Autoimmune manifestations, Transient lymphadenopathy, Flu-like symptoms / fever, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interleukin-7?
Recorded contraindications: Autoimmune disease, Hypersensitivity to IL-7 or excipients, Active graft-versus-host disease, Uncontrolled systemic infection, Hematologic malignancy with T-cell lineage involvement, Active autoimmune disease, severe lymphoproliferative disorders. Consult a qualified clinician before use.